neuraxon


Also found in: Medical.

neuraxon

(njʊrˈæksɒn)
n
(Biology) histology obsolete axon
References in periodicals archive ?
Finally, the myelin sheath, neuraxon, and Schwann cell nerve microstructures were observed under an electron microscope (JEOL Ltd.
At Ventures West, he currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics, NeurAxon and Presidio Pharmaceuticals.
NeurAxon, a Canadian company, has developed a first-in-class selective inhibitor of the neuronal form of NOS, which modulates the central and peripheral response to pain and neuronal sensitization.
Meanwhile, Ferrer Therapeutics has taken a different approach with its NeurAxon brain formula, basing the product on citicoline, a substance that the body produces naturally and one that constitutes approximately 30% of the gray matter in the human brain.
12 January 2010 - Pain therapeutics maker NeurAxon Inc said yesterday it has been awarded a USD267,000 (EUR184,137) grant from The Michael J.
s NeurAxon, a pharmaceutical-grade dietary supplement for brain function, is being introduced across the mass market after completing an exclusivity period at CVS/pharmacy.
Bloch served as chief executive officer of NeurAxon, Inc.
To attract these consumers, Ferrer Therapeutics markets a pharmaceutical-grade dietary supplement called NeurAxon that contains a neurotransmitter precursor (Citicoline) that Simpson says is important for normal brain function.
Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including NXN-188, an oral, first-in-class selective nNOS inhibitor and 5HT agonist and NXN-462, an oral selective nNOS inhibitor.
Andy is currently also Chairman and CEO of Kymab and is a non-executive director of NeurAxon and PBL.
The NeurAxon presentation will be delivered on Tuesday, November 16, 2010 at 2:10 pm Eastern Time at the St.
In this study we evaluated Total Migraine Freedom, the complete absence of all pain, nausea, and sensitivity to light and sound, and found that a significant proportion of patients receiving NXN-188 reported that all of their migraine symptoms had abated," said NeurAxon Chief Medical Officer, Robert Medve, M.